Lenacapavir (Sunlenca) (tabs and injection)
- Status:
- Do Not Prescribe (DNP)
- Decision Date:
- November 2022
Comments
Use in combination with other antiretroviral(s) for the treatment of
adults with multidrug‑resistant HIV‑1 infection for whom
it is otherwise not possible to construct a suppressive anti‑viral regimen Do Not Prescribe (DNP) Drug Classifications
- 2: Have a lack of data on safety compared with standard therapy
- 4: Have a lack of data on cost-effectiveness compared with standard therapy
- 5: Less cost-effective than current standard therapy
search again